Selective NIK Small-Molecule Inhibitors for Targeted Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases such as cancer, inflammatory disorders, autoimmune disorders, and metabolic disorders are inadequate due to the lack of effective inhibitors for NF-κB-inducing kinase (NIK), which plays a critical role in immune response disorders, cell proliferation, apoptosis, and carcinogenesis.
Innovation Solution
Development of small molecular inhibitors targeting NIK, including specific compounds of Formula (I) and their pharmaceutically acceptable salts, which can inhibit NIK activity to block downstream pathways involved in these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NIK inhibition is implemented to treat diseases, then therapeutic efficacy is improved, but severe immunosuppression occurs
Solution Approach 1:
The patent applies local quality by designing compounds that selectively inhibit NIK in specific pathological contexts (cancer cells, inflammatory tissues) while preserving NIK function in healthy immune cells. The compounds achieve differential inhibition based on local disease conditions, allowing therapeutic efficacy in affected tissues while minimizing systemic immunosuppression.
Solution Approach 2:
The patent employs parameter changes by optimizing compound structure (Formula I with specific R1-Rs substituents) to achieve selective NIK inhibition with altered kinetic properties. The compounds exhibit selective binding affinity and inhibition constants that enable preferential targeting of pathological NIK activity while sparing physiological immune responses.
2Reliability
If current treatments are used, then disease symptoms are managed, but specific NIK targeting is lacking
Solution Approach 1:
The patent applies segmentation by dividing the NIK inhibition function into specific molecular interactions defined by Formula I structures. The compounds segment the broad immune response into selective NIK pathway inhibition, achieving precise targeting of the kinase while leaving other immune pathways intact. This segmentation enables specific disease modification without blanket immunosuppression.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that specifically bind to NIK and block its catalytic activity. These intermediary compounds translate the therapeutic goal of NIK inhibition into concrete molecular action, providing precise targeting that biologics cannot achieve due to their larger size and different binding mechanisms.
3Reliability
If biologics are used to target NIK pathways, then clinical validation is achieved, but severe side effects occur
Solution Approach 1:
The patent employs small molecule compounds that are metabolically stable yet selectively inhibited in target tissues. These compounds act as temporary, reversible inhibitors that can be cleared or metabolized to restore normal NIK function when therapeutic effect is achieved, unlike biologics that require prolonged circulation and carry higher immunogenicity risks.
Solution Approach 2:
The patent changes the physical and chemical parameters from biologics (large proteins, peptide bonds, immunogenic) to small molecules (low molecular weight, stable bonds, non-immunogenic). This parameter transformation maintains clinical validity through selective NIK inhibition while eliminating the severe side effects associated with biologic therapies.
Data Source
AI summary
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.